How glycobiology can help us treat and beat the COVID-19 pandemic.
Antibodies, Neutralizing
/ therapeutic use
Antiviral Agents
/ chemistry
COVID-19
/ epidemiology
Drug Design
Drug Discovery
Drug Repositioning
Gene Expression
Glycomics
/ methods
Glycosaminoglycans
/ chemistry
Glycoside Hydrolase Inhibitors
/ therapeutic use
Glycosyltransferases
/ antagonists & inhibitors
Host-Pathogen Interactions
/ drug effects
Humans
Lectins
/ chemistry
Polysaccharides
/ chemistry
SARS-CoV-2
/ chemistry
Signal Transduction
Viral Proteins
/ antagonists & inhibitors
COVID-19
FDA-approved drugs
SARS-CoV-2
glycobiology
potential therapies
Journal
The Journal of biological chemistry
ISSN: 1083-351X
Titre abrégé: J Biol Chem
Pays: United States
ID NLM: 2985121R
Informations de publication
Date de publication:
Historique:
received:
27
10
2020
revised:
01
02
2021
accepted:
02
02
2021
pubmed:
7
2
2021
medline:
14
7
2021
entrez:
6
2
2021
Statut:
ppublish
Résumé
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged during the last months of 2019, spreading throughout the world as a highly transmissible infectious illness designated as COVID-19. Vaccines have now appeared, but the challenges in producing sufficient material and distributing them around the world means that effective treatments to limit infection and improve recovery are still urgently needed. This review focuses on the relevance of different glycobiological molecules that could potentially serve as or inspire therapeutic tools during SARS-CoV-2 infection. As such, we highlight the glycobiology of the SARS-CoV-2 infection process, where glycans on viral proteins and on host glycosaminoglycans have critical roles in efficient infection. We also take notice of the glycan-binding proteins involved in the infective capacity of virus and in human defense. In addition, we critically evaluate the glycobiological contribution of candidate drugs for COVID-19 therapy such as glycans for vaccines, anti-glycan antibodies, recombinant lectins, lectin inhibitors, glycosidase inhibitors, polysaccharides, and numerous glycosides, emphasizing some opportunities to repurpose FDA-approved drugs. For the next-generation drugs suggested here, biotechnological engineering of new probes to block the SARS-CoV-2 infection might be based on the essential glycobiological insight on glycosyltransferases, glycans, glycan-binding proteins, and glycosidases related to this pathology.
Identifiants
pubmed: 33548227
pii: S0021-9258(21)00147-2
doi: 10.1016/j.jbc.2021.100375
pmc: PMC7857991
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antiviral Agents
0
Glycosaminoglycans
0
Glycoside Hydrolase Inhibitors
0
Lectins
0
Polysaccharides
0
Viral Proteins
0
Glycosyltransferases
EC 2.4.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
100375Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest The authors declare that they have no conflicts of interest with the contents of this article.
Références
Sci Rep. 2016 Jan 19;6:19509
pubmed: 26781493
J Virol. 2021 Jan 13;95(3):
pubmed: 33173010
J Virol. 1995 Apr;69(4):2233-9
pubmed: 7884870
J Biomol Struct Dyn. 2021 Oct;39(16):6265-6280
pubmed: 32705952
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Science. 2013 May 10;340(6133):711-6
pubmed: 23539181
Commun Biol. 2021 Apr 12;4(1):475
pubmed: 33846513
Glycobiology. 2021 May 3;31(4):378-384
pubmed: 32985653
Emerg Microbes Infect. 2020 Dec;9(1):727-732
pubmed: 32196410
Am J Cardiovasc Drugs. 2018 Dec;18(6):427-440
pubmed: 30066080
FEBS J. 2005 Dec;272(24):6179-217
pubmed: 16336259
J Med Chem. 2020 Jan 23;63(2):747-755
pubmed: 31846326
Clin Transl Immunology. 2020 Mar 17;9(3):e01120
pubmed: 32194962
Microorganisms. 2020 Mar 13;8(3):
pubmed: 32183205
J Clin Endocrinol Metab. 2011 May;96(5):E782-92
pubmed: 21346065
Infect Chemother. 2013 Mar;45(1):11-21
pubmed: 24265946
J Biomol Struct Dyn. 2021 Sep;39(14):5129-5136
pubmed: 32597315
J Cell Biol. 1992 Mar;116(5):1273-81
pubmed: 1310996
PLoS One. 2020 Sep 11;15(9):e0238907
pubmed: 32915876
Immunol Cell Biol. 2008 Oct;86(7):580-7
pubmed: 18679407
J Virol. 2021 Jan 28;95(4):
pubmed: 33219167
Nature. 2021 Mar;591(7849):293-299
pubmed: 33494095
Expert Opin Ther Pat. 2014 Oct;24(10):1053-65
pubmed: 25109359
Int J Mol Sci. 2020 Sep 16;21(18):
pubmed: 32947858
Nat Med. 2020 Apr;26(4):450-452
pubmed: 32284615
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Biomol Struct Dyn. 2022 Feb;40(3):1299-1315
pubmed: 32969333
PLoS One. 2011;6(8):e23710
pubmed: 21887302
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Biochim Biophys Acta Gen Subj. 2019 Oct;1863(10):1480-1497
pubmed: 31121217
Chin J Integr Med. 2020 Sep;26(9):663-669
pubmed: 32740825
Sci Rep. 2017 Oct 17;7(1):13412
pubmed: 29042614
Proc Natl Acad Sci U S A. 2020 Jan 21;117(3):1438-1446
pubmed: 31900356
Vaccines (Basel). 2021 Jan 11;9(1):
pubmed: 33440895
Tissue Antigens. 2006 Sep;68(3):193-209
pubmed: 16948640
Science. 2010 Apr 16;328(5976):357-60
pubmed: 20339031
Cell. 2020 Nov 12;183(4):1043-1057.e15
pubmed: 32970989
Annu Rev Virol. 2020 Sep 29;7(1):143-165
pubmed: 32396772
J Mol Graph Model. 2020 Nov;100:107697
pubmed: 32739642
Immunol Rev. 2016 Mar;270(1):32-50
pubmed: 26864103
Sci Rep. 2020 Oct 1;10(1):16200
pubmed: 33004837
Antivir Chem Chemother. 2020 Jan-Dec;28:2040206620961712
pubmed: 32972196
J Mol Biol. 2021 Jan 22;433(2):166725
pubmed: 33245961
Curr Trends Immunol. 2020;21:17-23
pubmed: 32606565
Drug Deliv Transl Res. 2020 Dec;10(6):1644-1674
pubmed: 32588282
Proc Natl Acad Sci U S A. 2021 May 11;118(19):
pubmed: 33903171
J Infect Dis. 2005 Oct 15;192(8):1355-61
pubmed: 16170752
Cells. 2020 Jul 09;9(7):
pubmed: 32660065
Nat Microbiol. 2020 Apr;5(4):562-569
pubmed: 32094589
Biochem Med Metab Biol. 1993 Aug;50(1):111-9
pubmed: 8373631
Lancet Infect Dis. 2020 Jul;20(7):793-802
pubmed: 32247326
PLoS One. 2015 Mar 25;10(3):e0119298
pubmed: 25807519
Int Immunol. 2005 May;17(5):661-9
pubmed: 15802303
Res Pract Thromb Haemost. 2020 Jun 09;4(4):518-523
pubmed: 32542212
Cent Eur J Immunol. 2018;43(4):466-475
pubmed: 30799995
PLoS One. 2020 Oct 15;15(10):e0240653
pubmed: 33057452
Nat Commun. 2020 May 27;11(1):2688
pubmed: 32461612
Pediatr Allergy Immunol. 2020 Jul;31(5):454-470
pubmed: 32359201
Front Immunol. 2019 Mar 19;10:483
pubmed: 30941130
Antiviral Res. 2020 Jun;178:104787
pubmed: 32251768
Nature. 2020 Dec;588(7837):327-330
pubmed: 32942285
Chembiochem. 2020 Mar 2;21(5):730-738
pubmed: 32022370
J Clin Invest. 1969 Jul;48(7):1280-91
pubmed: 4893685
Mem Inst Oswaldo Cruz. 2020 Sep 30;115:e200207
pubmed: 33027419
J Virol. 2007 Apr;81(7):3487-94
pubmed: 17202212
J Infect Dis. 2005 May 15;191(10):1697-704
pubmed: 15838797
Science. 2020 Mar 27;367(6485):1444-1448
pubmed: 32132184
J Dent. 2019 Jan;80 Suppl 1:S3-S12
pubmed: 30696553
Med Hypotheses. 2020 Nov;144:109984
pubmed: 32554149
Med Hypotheses. 2020 Nov;144:110024
pubmed: 32758871
Glycobiology. 2020 Dec 9;30(12):981-988
pubmed: 32363391
PLoS Biol. 2009 Apr 28;7(4):e95
pubmed: 19402752
Nat Immunol. 2006 Nov;7(11):1200-8
pubmed: 16998493
Nat Med. 2020 May;26(5):672-675
pubmed: 32296168
Chembiochem. 2020 Nov 2;21(21):2999-3025
pubmed: 32426893
J Cell Physiol. 2021 Apr;236(4):2959-2975
pubmed: 32959892
Sci Transl Med. 2010 Mar 24;2(24):24ra21
pubmed: 20375007
Front Public Health. 2020 Aug 21;8:497
pubmed: 32974268
Lancet. 2020 Oct 3;396(10256):959-967
pubmed: 32896292
J Thorac Dis. 2019 Sep;11(Suppl 14):S1740-S1754
pubmed: 31632751
Glycobiology. 2021 May 3;31(4):410-424
pubmed: 33135055
J Infect. 2015 Jul;71(1):101-9
pubmed: 25818534
Proc Natl Acad Sci U S A. 2018 Jul 10;115(28):7320-7325
pubmed: 29941589
ACS Cent Sci. 2020 Oct 28;6(10):1722-1734
pubmed: 33140034
PLoS Pathog. 2018 Aug 13;14(8):e1007236
pubmed: 30102747
Cell Host Microbe. 2020 Oct 7;28(4):586-601.e6
pubmed: 32841605
J Clin Med. 2020 May 14;9(5):
pubmed: 32422996
Science. 1999 Dec 10;286(5447):2156-9
pubmed: 10591647
Viruses. 2019 Jul 01;11(7):
pubmed: 31266258
Biochem Soc Trans. 2020 Jun 30;48(3):1287-1295
pubmed: 32510142
Infect Dis Poverty. 2020 Apr 28;9(1):45
pubmed: 32345362
J Biomol Struct Dyn. 2021 Jun;39(9):3347-3357
pubmed: 32362245
Molecules. 2015 Jan 29;20(2):2229-71
pubmed: 25642836
Blood Adv. 2020 Oct 27;4(20):4981-4989
pubmed: 33057633
Jpn J Infect Dis. 2004 Dec;57(6):236-47
pubmed: 15623947
Lancet. 2020 Feb 22;395(10224):542-545
pubmed: 32061313
J Med Virol. 2020 Feb;92(2):129-138
pubmed: 31502669
Sci Rep. 2019 May 30;9(1):8097
pubmed: 31147593
Cell. 2019 Feb 21;176(5):1026-1039.e15
pubmed: 30712865
Sci Rep. 2019 Feb 18;9(1):2186
pubmed: 30778105
Glycobiology. 2008 Dec;18(12):1085-93
pubmed: 18818423
J Biol Chem. 2001 Aug 3;276(31):28939-45
pubmed: 11384997
J Mol Graph Model. 2020 Dec;101:107716
pubmed: 32866780